1. Home
  2. APLT vs YGMZ Comparison

APLT vs YGMZ Comparison

Compare APLT & YGMZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • APLT
  • YGMZ
  • Stock Information
  • Founded
  • APLT 2016
  • YGMZ 2002
  • Country
  • APLT United States
  • YGMZ China
  • Employees
  • APLT N/A
  • YGMZ N/A
  • Industry
  • APLT Biotechnology: Pharmaceutical Preparations
  • YGMZ Transportation Services
  • Sector
  • APLT Health Care
  • YGMZ Consumer Discretionary
  • Exchange
  • APLT Nasdaq
  • YGMZ Nasdaq
  • Market Cap
  • APLT 80.3M
  • YGMZ 73.6M
  • IPO Year
  • APLT 2019
  • YGMZ 2020
  • Fundamental
  • Price
  • APLT $0.52
  • YGMZ $0.76
  • Analyst Decision
  • APLT Buy
  • YGMZ
  • Analyst Count
  • APLT 7
  • YGMZ 0
  • Target Price
  • APLT $6.10
  • YGMZ N/A
  • AVG Volume (30 Days)
  • APLT 1.6M
  • YGMZ 41.0K
  • Earning Date
  • APLT 05-08-2025
  • YGMZ 01-01-0001
  • Dividend Yield
  • APLT N/A
  • YGMZ N/A
  • EPS Growth
  • APLT N/A
  • YGMZ N/A
  • EPS
  • APLT N/A
  • YGMZ N/A
  • Revenue
  • APLT N/A
  • YGMZ $55,805,416.00
  • Revenue This Year
  • APLT N/A
  • YGMZ N/A
  • Revenue Next Year
  • APLT $2,426.33
  • YGMZ N/A
  • P/E Ratio
  • APLT N/A
  • YGMZ N/A
  • Revenue Growth
  • APLT N/A
  • YGMZ N/A
  • 52 Week Low
  • APLT $0.43
  • YGMZ $0.64
  • 52 Week High
  • APLT $10.62
  • YGMZ $4.35
  • Technical
  • Relative Strength Index (RSI)
  • APLT 43.47
  • YGMZ 40.30
  • Support Level
  • APLT $0.52
  • YGMZ $0.80
  • Resistance Level
  • APLT $0.62
  • YGMZ $0.99
  • Average True Range (ATR)
  • APLT 0.05
  • YGMZ 0.11
  • MACD
  • APLT 0.01
  • YGMZ -0.02
  • Stochastic Oscillator
  • APLT 23.19
  • YGMZ 1.90

About APLT Applied Therapeutics Inc.

Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.

About YGMZ MingZhu Logistics Holdings Limited

MingZhu Logistics Holdings Ltd is a Holding company. Its business activities include trucking services and car owner services. Its segments are the trucking business, car owner services business, and liquor distribution business. It generates the majority of its revenue from the trucking segment.

Share on Social Networks: